Abraxis backs SPARC as prognostic biomarker
SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.
SPARC (secreted protein acidic and rich in cysteine) may play a role in tumor growth and angiogenesis, according to preclinical data presented at AACR 2009.
Researchers at Abraxis BioScience, the manufacturer of Abraxane (nab-paclitaxel), found that recombinant human SPARC grown in vitro fostered angiogenesis and the development of mature blood vessels. SPARC may play a greater role in the angiogenic process beyond initiating the growth of new blood vessels, they said (abstracts 1478, 2572, 3769, 4017, 5168).
Articles in this issue
ADT in prostate ca increases risk of bone and heart complications
Abraxis backs SPARC as prognostic biomarker
ALK-1 receptor: New target in angiogenesis
Abraxane prolongs PFS in metastatic disease
SAVI applicator removes obstacles associated with brachytherapy
Mistrust, costs reduce breast cancer screening among minorities
Oral chemotherapy poses more challenges for cancer community
CMS nixes CT colonography screening
New ultrasound strategy helps pinpoint prostate tumors
New research on VEGF, gene mutations refines understanding of tumor angiogenesis
From the ONI archives: Should low-dose induction dexamethasone be standard of care in multiple myeloma?
Persistent circulating tumor cells predict worse outcomes in early breast cancer
Genomics takes center stage at AACR in chemoprevention and disease treatment
Gefitinib changes first-line Rx for lung ca in Asian pts
Who's News
Recent Videos
![“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9b290688648a249e516474c175a3c06309426d15-2950x1568.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.")
Related Content
